<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The membrane expression of CD45RA and CD45RO on fresh leukaemic cells taken from 529 cases of <z:hpo ids='HP_0011009'>acute</z:hpo> haemopoietic <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including 117 B-origin <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (B-origin ALL), 37 T-origin <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (T-origin ALL0, 297 de novo <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 42 refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) and 36 myeloid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>-BP-my), was analysed </plain></SENT>
<SENT sid="1" pm="."><plain>B-origin ALLs were characterized by the lack of the RO isoform along with the consistent presence of RA </plain></SENT>
<SENT sid="2" pm="."><plain>Conversely, a differential expression of the two isoforms was detected in different subsets of T-origin ALL, in that T-stem cell <z:mpath ids='MPATH_336'>leukaemias</z:mpath> (T-SCL: CD7+, CD4-, CD8-, CD1-) preferentially expressed CD45RA whereas conventional T-<z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemias</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>: CD7+, CD4+ and/or CD8+ and/or CD1+) were consistently marked by CD45RO </plain></SENT>
<SENT sid="3" pm="."><plain>Within <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e>, most of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e> displayed CD45RA, while a substantial group of <z:mp ids='MP_0005481'>CML</z:mp>-BP-my preferentially exhibited CD45RO </plain></SENT>
<SENT sid="4" pm="."><plain>As a general rule, a reciprocal exclusion of the two isoforms was observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> as well as in ALL </plain></SENT>
<SENT sid="5" pm="."><plain>Nevertheless, a frequent coexpression of CD45RA and CD45RO was observed in CD14+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In vitro treatment with <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) was able to promote a switch from CD45RA to CD45RO expression in 27 de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, independently from morphological subtyping </plain></SENT>
<SENT sid="7" pm="."><plain>To our knowledge, this is the first report on CD45 isoform expression in a large series of patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>The knowledge of the differential expression of CD45RA and CD45RO can ameliorate our classificative approach to <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e>, as well as disclose new multiple overlap points between <z:mpath ids='MPATH_458'>normal</z:mpath> and leukaemic cell differentiation </plain></SENT>
</text></document>